The US Food and Drug Administration (FDA) on Tuesday issued final guidance meant to assist drug and medical device makers in developing risk-based monitoring strategies for clinical investigations ...

David Benigson is CEO of Signal AI, a company using AI and media data to help executives cut through noise and drive actionable insights. Risk is no longer a four-letter word—it's a critical factor ...

The U.S. Food and Drug Administration (FDA) recently finalized its guidance, “A Risk-Based Approach to Monitoring of Clinical Investigations” (the “2023 RBM Guidance”) which follows up on the Agency’s ...

The American Gastroenterology Association (AGA) Institute issued new clinical practice guidelines, providing evidence-based recommendations for managing hepatitis B reactivation (HBVr) in at-risk ...

Organizations are integrating previously disparate services to better align their offerings with the shift from fee-for-service to risk-based care through visionary, member-centric solutions. For ...

Clinical trials can often take between six and seven years to complete, but that timeline isn’t always practical for the problems pharmaceutical companies are trying to solve. Additionally, six years ...

US and EU officials explained on Wednesday what their respective regulatory agencies look for in clinical trial risk-based monitoring (RBM) and how RBM can impact review times. Under a cooperative ...

Portfolio risk management tools are an essential part of your firm's tech stack. These platforms help you spot risks, compare exposures, and adjust portfolios to match each client's risk tolerance and ...

NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Dow Jones Risk & Compliance has today announced a new advanced, AI-powered solution for financial crime and third-party risk management. RiskCenter ...